KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) had its price objective reduced by HC Wainwright from $24.00 to $20.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Separately, Needham & Company LLC reiterated a buy rating and set a $35.00 price […]
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 191.67% from the stock’s […]
KalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 52-Week High on Analyst Upgrade themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) shares gapped up before the market opened on Friday following insider buying activity. The stock had previously closed at $14.90, but opened at $15.47. KalVista Pharmaceuticals shares last traded at $15.38, with a volume of 33,479 shares changing hands. Specifically, major shareholder Venrock Healthcare Capital Par purchased […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par bought 4,174 shares of the business’s stock in a transaction on Friday, January 26th. The stock was purchased at an average cost of $12.98 per share, for a total transaction of $54,178.52. Following the transaction, the insider now owns 4,569,984 shares […]